Free tool
FAERS Monitor: Revuforj
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 218944 or its brand name (Revuforj, Revumenib Citrate). Reports on generic versions are filed under their own applications.
Reports
1,031
Serious
628
61% of reports
Hospitalization
308
Death reported
137
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use310
- nausea172
- platelet count decreased160
- product dose omission issue121
- fatigue110
- death104
- vomiting77
- white blood cell count decreased73
- pyrexia63
- haemoglobin decreased51
- diarrhoea50
- electrocardiogram qt prolonged49
- full blood count decreased49
- thrombocytopenia49
- differentiation syndrome47
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2024 | 10 |
| 2025 | 545 |
| 2026 | 476 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,128 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| differentiation syndromeSignal | 47 | 1397.0 | 1046.2 | 60,069 |
| full blood count decreasedSignal | 49 | 49.7 | 37.8 | 2,288 |
| platelet count decreasedSignal | 160 | 30.7 | 26.6 | 4,579 |
| electrocardiogram qt prolongedSignal | 49 | 27.8 | 21.2 | 1,241 |
| white blood cell count decreasedSignal | 73 | 13.7 | 11.0 | 854 |
| haemoglobin decreasedSignal | 51 | 10.1 | 7.8 | 413 |
| thrombocytopeniaSignal | 49 | 8.9 | 6.8 | 339 |
| product dose omission issueSignal | 121 | 8.4 | 7.1 | 792 |
| off label useSignal | 310 | 7.2 | 6.6 | 1,728 |
| nauseaSignal | 172 | 4.4 | 3.9 | 472 |
| pyrexiaSignal | 63 | 3.7 | 2.9 | 124 |
| vomitingSignal | 77 | 3.3 | 2.7 | 127 |
| fatigueSignal | 110 | 2.9 | 2.4 | 138 |
| deathSignal | 104 | 2.5 | 2.1 | 93 |
| diarrhoea | 50 | 1.6 | 1.2 | 10 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.